Tenaya Therapeutics Enters Strategic Collaboration with Alnylam, Securing Up to $10M Upfront and $1.13B in Milestones
TNYA sits 78% above its 52-week low of $0.36.
Summary
Tenaya Therapeutics has entered a research collaboration with Alnylam Pharmaceuticals, receiving an upfront payment of up to $10 million and eligibility for up to $1.13 billion in development, regulatory, and sales-based milestones.
Key Events · M&A and Partnerships · TNYA
-
Strategic Collaboration with Alnylam Pharmaceuticals
Tenaya Therapeutics has partnered with Alnylam Pharmaceuticals for a research collaboration focused on discovering and validating novel gene targets for cardiovascular disease.
-
Significant Upfront Payment Received
The company will receive an upfront payment of up to $10.0 million from Alnylam, providing a substantial cash injection for its operations.
-
Potential for Over $1 Billion in Milestone Payments
Tenaya is eligible to receive up to an aggregate of $1.13 billion in development, regulatory, and sales-based milestones for products directed to Company-nominated targets.
-
Exclusive Licensing and Research Focus
Tenaya granted Alnylam an exclusive, worldwide license for collaboration targets, with Alnylam taking sole responsibility for development, manufacturing, regulatory, and commercialization post-validation activities.
Analysis · TNYA · Life Sciences
This collaboration with Alnylam Pharmaceuticals is a highly significant event for Tenaya Therapeutics, providing a substantial upfront cash infusion relative to its market capitalization and validating its gene target discovery platform. The potential for over $1 billion in milestone payments, while contingent, represents a massive long-term value proposition. This strategic partnership with a major pharmaceutical company offers critical non-dilutive funding and external validation, which is particularly impactful given the recent pattern of significant insider selling by a 10% owner. The agreement extends Tenaya's financial runway and de-risks its research efforts in cardiovascular disease, shifting development and commercialization costs for successful targets to Alnylam.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 41.9% of the 327 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TNYA was trading at $0.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $125.9M. The 52-week trading range was $0.36 to $2.35. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.